AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Phase 2
Completed
- Conditions
- Gastrointestinal Stromal TumorsSoft Tissue Sarcomas
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00385203
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
PPI Sequencing Study
Phase 4
Completed
- Conditions
- Gastro-Oesophageal Reflux Disease
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00384592
- Locations
- 🇬🇧
Research Site, Warminster, United Kingdom
🇬🇧Research SIte, Glasgow, United Kingdom
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1080
- Registration Number
- NCT00384189
- Locations
- 🇺🇦
Altana Pharma/Nycomed, Zaporizhzhya, Ukraine
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1814
- Registration Number
- NCT00384176
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1979
- Registration Number
- NCT00383929
- Locations
- 🇩🇪
Research SIte, Hann, Germany
🇬🇧Research Site, Wokingham, United Kingdom
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 153
- Registration Number
- NCT00382239
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Safety and Efficacy of Exenatide as Monotherapy
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT00381342
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Rosuvastatin ORBITAL Germany
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8000
- Registration Number
- NCT00379249
Airway Clearance Study
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00379028
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
Phase 2
Completed
- Conditions
- Renal Cell CarcinomaPatients Who Have/Have Had Melanoma and Other TumorsColorectal NeoplasmsProstatic NeoplasmsNeoplasmsMelanoma
- Interventions
- Drug: CP-675,206 (Tremelimumab)
- First Posted Date
- 2006-09-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00378482
- Locations
- 🇬🇧
Research Site, Newecastle Upon Tyne, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath